Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31371189 | 0.88 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1861575 | 0.88 | CA1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12808621 | 0.88 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17083284 | 0.86 | LOXL2 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30469443 | 0.86 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18216620 | 0.86 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1756375 | 0.86 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12487744 | 0.86 | MAPT (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4123831 | 0.86 | DPP4 (0.51) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL17077484 | 0.85 | LOXL2 (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025090928-A9 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025090928-A1 | COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | AQUINNAH PHARMACEUTICALS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129047-A2 | NOVEL MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129041-A1 | PRODRUGS OF 3-BENZOAMIDO-2-AMINOPROPIONIC ACID DERIVATIVES AS MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022128843-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | disclosed |
| EP-3562822-B1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CA12 4392/4885CA1 4516/4885CA2 2821/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CA12 4392/4885CA1 4516/4885CA2 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.